Edwards Lifesciences (EW) revenue breakdown
By segment, United States is the largest at 58% of fiscal 2025 revenue; Europe grew fastest, 8% a year over 8 years.
By product, Transcatheter Aortic Valve Replacement is the largest at 74% of fiscal 2025 revenue; Transcatheter Mitral and Tricuspid Therapies grew fastest, 89% a year over 8 years.
Revenue by segment
Fiscal years, as Edwards Lifesciences reports them in its 10-K filings; fiscal 2025 total $6.1B.
| Segments | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| United States | $1.9B | $2.1B | $2.5B | $2.5B | $3.0B | $2.6B | $2.9B | $3.2B | $3.5B | 58% |
| Europe | $801M | $826M | $926M | $945M | $1.1B | $1.0B | $1.2B | $1.3B | $1.5B | 25% |
| Rest of World | $357M | $396M | $433M | $452M | $533M | $436M | $531M | $572M | $652M | 11% |
| Japan | $356M | $398M | $441M | $449M | $528M | $360M | $351M | $340M | $355M | 6% |
Revenue by product
Fiscal years, as Edwards Lifesciences reports them in its 10-K filings; fiscal 2025 total $6.1B.
| Products | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| Transcatheter Aortic Valve Replacement | $2.0B | $2.3B | $2.7B | $2.9B | $3.4B | $3.5B | $3.9B | $4.1B | $4.5B | 74% |
| Surgical Structural Heart | $807M | $762M | $842M | $762M | $889M | $830M | $933M | $981M | $1.0B | 17% |
| Transcatheter Mitral and Tricuspid Therapies | $3M | $3M | $28M | $42M | $86M | $116M | $198M | $352M | $551M | 9% |
| Critical Care | $601M | $674M | $740M | $725M | $835M | — | — | — | — | — |
Revenue by region
Fiscal years, as Edwards Lifesciences reports them in its 10-K filings; fiscal 2023 total $6.0B.
| Regions | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | Share |
|---|---|---|---|---|---|---|---|---|
| United States | $1.9B | $2.1B | $2.5B | $2.5B | $3.0B | $3.1B | $3.5B | 58% |
| Europe | $831M | $885M | $941M | $974M | $1.2B | $1.2B | $1.3B | 22% |
| Rest of World | $346M | $386M | $429M | $436M | $550M | $601M | $709M | 12% |
| Japan | $350M | $397M | $445M | $460M | $529M | $474M | $452M | 8% |
Questions
Where does Edwards Lifesciences make its money?
In fiscal 2025, by segment: United States $3.5B, Europe $1.5B, Rest of World $652M, Japan $355M.
From Edwards Lifesciences's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.